Skip to main content

BBIO

Stock
Health Care
Biotechnology

Performance overview

BBIO Price
Price Chart

Forward-looking statistics

Beta
1.45
Risk
64.26%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.

Company info

SectorHealth Care
IndustryBiotechnology
Employees444
Market cap$5.1B

Fundamentals

Enterprise value$9.5B
Revenue$127.4M
Revenue per employee
Profit margin98.25%
Debt to equity-1.13

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$3.56
Dividend per share
Revenue per share$0.67
Avg trading volume (30 day)$139M
Avg trading volume (10 day)$182M
Put-call ratio

Macro factor sensitivity

Growth-1.0
Credit+6.1
Liquidity+1.8
Inflation-4.2
Commodities-1.3
Interest Rates-4.6

Valuation

Dividend yield0.00%
PEG Ratio-14.38
Price to sales65.56
P/E Ratio-14.38
Enterprise Value to Revenue74.77
Price to book

Upcoming events

Next earnings dayApril 30, 2025
Next dividend day
Ex. dividend day

News

It is time for a move higher in biotech, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.

CNBC Television (July 7, 2025)
Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 63.9% in BridgeBio Pharma (BBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research (May 13, 2025)
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug

The Japanese Ministry of Health, Labour and Welfare on Thursday approved BridgeBio Pharma, Inc.'s BBIO acoramidis, under the brand name Beyonttra, for adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Benzinga (March 27, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free